StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
20
This year
1
Publishing Date
2024 - 02 - 06
1
2023 - 09 - 26
1
2023 - 05 - 04
1
2022 - 10 - 24
1
2022 - 07 - 06
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 02 - 23
1
2022 - 02 - 17
1
2022 - 02 - 01
1
2022 - 01 - 31
1
2021 - 10 - 13
1
2021 - 09 - 20
1
2021 - 09 - 09
1
2021 - 06 - 25
1
2021 - 06 - 10
1
2020 - 12 - 14
1
Sector
Health technology
20
Tags
Agreement
2
Application
1
Asco
1
Authorization
2
Breast cancer
3
Cancer
9
Clearance
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
4
Clinical-trials-phase-iii
6
Collaboration
1
Covid
1
Covid-19
8
Designation
1
Disease
1
Drug
1
Emergency use authorization
2
Endocrine
1
Enroll
3
Fast track
1
Fast track designation
1
Fda
6
Grant
1
Granted
1
Hormone
1
Injection
1
Metastatic breast cancer
3
N/a
9
Oxygen
1
Phase 1
3
Phase 1b
3
Phase 2
3
Phase 2b
4
Phase 3
7
Positive
5
Presentation
5
Prostate cancer
6
Publication
1
Respiratory
2
Results
2
Risk
2
Sabizabulin
14
State
1
Symposium
1
Syndros
1
Test
1
Therapy
1
Treat
1
Treatment
6
Trial
10
Trial results
1
Verzenio
1
Week
1
Entities
4d molecular therapeutics inc
24
Abb ltd
72
Abbvie inc.
62
Actinium pharmaceuticals, inc.
28
Aldeyra therapeutics, inc.
38
Alnylam pharmaceuticals, inc.
38
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Amgen inc.
25
Anavex life sciences corp.
24
Arcutis biotherapeutics, inc.
29
Arrival
26
Arrowhead pharmaceuticals, inc.
23
Astellas pharma inc
26
Astrazeneca plc
64
Beigene, ltd.
35
Biogen inc.
23
Biovie inc.
28
Bioxcel therapeutics, inc.
26
Bristol-myers squibb company
73
Clearside biomedical, inc.
24
Clene inc
25
Cnh industrial n.v.
69
Cybin inc
26
Cytokinetics, incorporated
29
Dynavax technologies corporation
28
Eli lilly and company
161
Enlivex therapeutics ltd.
26
Exelixis, inc.
28
Fortress biotech, inc.
41
Gates industrial corporation plc
25
Gilead sciences, inc.
48
Global industrial co
38
Honeywell international inc.
53
Horizon therapeutics public limited company
46
I-mab
34
Icon plc
43
Immix biopharma, inc.
26
Immutep limited
34
Incyte corporation
49
Johnson & johnson
203
Medtronic plc
25
Merck & company, inc.
72
Moleculin biotech, inc.
34
Novartis ag
34
Novo nordisk a/s
42
Ocugen, inc.
27
Orange
91
Pds biotechnology corporation
25
Pfizer, inc.
61
Plus therapeutics, inc.
35
Regeneron pharmaceuticals, inc.
44
Regenxbio inc.
29
Sanofi
311
Sellas life sciences group, inc.
24
Sorrento therapeutics, inc.
38
Stag industrial, inc.
32
Takeda pharmaceutical company limited
56
Tg therapeutics, inc.
27
Thermo fisher scientific inc
48
Symbols
GILD
2
LLY
11
VERU
20
Exchanges
Nasdaq
20
Nyse
11
Crawled Date
2024 - 02 - 06
1
2023 - 09 - 26
1
2023 - 05 - 04
1
2022 - 10 - 24
1
2022 - 07 - 06
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 02 - 23
1
2022 - 02 - 17
1
2022 - 02 - 01
1
2022 - 01 - 31
1
2021 - 10 - 13
1
2021 - 09 - 20
1
2021 - 09 - 09
1
2021 - 06 - 25
1
2021 - 06 - 10
1
2020 - 12 - 14
1
Crawled Time
11:00
2
12:00
3
13:00
4
13:01
1
13:15
2
13:20
1
14:00
4
14:30
3
Source
www.biospace.com
11
www.globenewswire.com
9
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
entities :
Veru inc.
save search
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Published:
2024-02-06
(Crawled : 14:00)
- globenewswire.com
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
159.18%
|
O:
-1.04%
H:
1.51%
C:
-9.12%
fda
treat
clearance
application
trial
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published:
2023-09-26
(Crawled : 13:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
32.42%
|
O:
-0.17%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
50.81%
|
O:
5.69%
H:
3.37%
C:
-10.11%
fda
sabizabulin
respiratory
trial
agreement
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published:
2023-05-04
(Crawled : 12:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
69.61%
|
O:
0.06%
H:
0.29%
C:
-0.7%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
0.0%
|
O:
0.0%
H:
2.36%
C:
0.0%
covid-19
fda
sabizabulin
treatment
risk
trial
agreement
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published:
2022-10-24
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
114.61%
|
O:
1.01%
H:
2.19%
C:
1.07%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-88.64%
|
O:
0.63%
H:
0.6%
C:
-3.2%
covid-19
treatment
sabizabulin
disease
oxygen
week
presentation
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published:
2022-07-06
(Crawled : 12:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
127.09%
|
O:
1.85%
H:
1.45%
C:
0.66%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-88.98%
|
O:
0.26%
H:
20.43%
C:
12.73%
covid-19
treatment
sabizabulin
trial
results
publication
phase 3
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 11:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
141.33%
|
O:
3.83%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-90.26%
|
O:
10.2%
H:
0.0%
C:
0.0%
sabizabulin
trial
presentation
positive
cancer
phase 2b
prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published:
2022-05-11
(Crawled : 11:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
150.52%
|
O:
-3.03%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-84.13%
|
O:
20.75%
H:
0.0%
C:
0.0%
covid-19
fda
sabizabulin
authorization
positive
phase 3
emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published:
2022-05-02
(Crawled : 13:20)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
148.49%
|
O:
-0.92%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-89.16%
|
O:
8.28%
H:
2.44%
C:
-19.07%
covid-19
fda
sabizabulin
granted
authorization
positive
phase 3
emergency use authorization
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published:
2022-04-25
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
153.73%
|
O:
-3.29%
H:
2.58%
C:
2.31%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-88.67%
|
O:
0.89%
H:
27.06%
C:
24.67%
covid-19
treatment
sabizabulin
presentation
phase 2
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published:
2022-04-11
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
134.63%
|
O:
0.45%
H:
0.21%
C:
-1.32%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-70.8%
|
O:
37.7%
H:
143.24%
C:
105.01%
covid-19
drug
sabizabulin
phase 3
Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy
Published:
2022-02-23
(Crawled : 14:00)
- biospace.com/
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-76.57%
|
O:
2.12%
H:
1.54%
C:
-3.88%
therapy
cancer
breast cancer
metastatic breast cancer
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published:
2022-02-17
(Crawled : 14:30)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
197.8%
|
O:
0.0%
H:
0.0%
C:
-1.88%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-79.78%
|
O:
-0.96%
H:
0.88%
C:
-3.38%
prostate cancer
symposium
state
phase 1b
presentation
asco
phase 1
cancer
sabizabulin
phase 2b
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Published:
2022-02-01
(Crawled : 14:30)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
199.99%
|
O:
1.37%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-75.58%
|
O:
2.21%
H:
4.99%
C:
4.05%
verzenio
trial
collaboration
phase 3
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published:
2022-01-31
(Crawled : 14:30)
- biospace.com/
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-73.21%
|
O:
1.69%
H:
8.74%
C:
7.88%
covid-19
fast track designation
treatment
fda
risk
fast track
respiratory
covid
grant
syndros
sabizabulin
designation
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Published:
2021-10-13
(Crawled : 13:00)
- globenewswire.com
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-85.04%
|
O:
0.94%
H:
3.85%
C:
2.68%
test
cancer
phase 3
breast cancer
trial
enroll
metastatic breast cancer
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published:
2021-09-20
(Crawled : 13:15)
- biospace.com/
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-85.79%
|
O:
-4.25%
H:
3.62%
C:
-1.17%
GILD
|
$67.03
0.12%
0.12%
5.2M
|
Health Technology
|
-5.48%
|
O:
0.14%
H:
1.4%
C:
0.04%
prostate cancer
phase 1
positive
cancer
phase 1b
sabizabulin
phase 2b
Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published:
2021-09-09
(Crawled : 13:15)
- biospace.com/
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-86.31%
|
O:
-1.31%
H:
5.75%
C:
3.73%
GILD
|
$67.03
0.12%
0.12%
5.2M
|
Health Technology
|
-6.86%
|
O:
-0.33%
H:
0.06%
C:
-1.44%
presentation
prostate cancer
phase 1
cancer
phase 1b
sabizabulin
phase 2b
Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
Published:
2021-06-25
(Crawled : 13:00)
- globenewswire.com
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-84.55%
|
O:
1.46%
H:
0.96%
C:
-1.8%
prostate cancer
cancer
phase 3
trial
enroll
sabizabulin
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
Published:
2021-06-10
(Crawled : 13:00)
- globenewswire.com
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-85.92%
|
O:
-0.33%
H:
0.89%
C:
-1.0%
treatment
phase 2
prostate cancer
injection
cancer
trial
hormone
enroll
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published:
2020-12-14
(Crawled : 13:01)
- globenewswire.com
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-80.02%
|
O:
55.31%
H:
9.73%
C:
-1.77%
results
breast cancer
cancer
positive
endocrine
trial
trial results
phase 2
metastatic breast cancer
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.